PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma

British Journal of Dermatology

Volumn 176, Issue 1, 2017, Pages 216-219

  Winkler, J K ^a   Bender, C ^a   Kratochwil, C ^b   Enk, A ^a   Hassel, J C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Department of Nuclear Medicine ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METOPROLOL; PEMBROLIZUMAB; THIAMAZOLE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADRENAL METASTASIS; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; HUMAN; HYPERTHYROIDISM; LYMPH NODE METASTASIS; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; SUPRACLAVICULAR LYMPH NODE; TACHYCARDIA; TREATMENT RESPONSE; VERY ELDERLY; ADRENAL TUMOR; ANTAGONISTS AND INHIBITORS; CARCINOMA, MERKEL CELL; MALE; POSITRON EMISSION TOMOGRAPHY; SECONDARY; SKIN NEOPLASMS;

ADRENAL GLAND NEOPLASMS; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; HUMANS; LYMPHATIC METASTASIS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84997040246     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14632     Document Type: Article

References (18)

1. Rabinowits G. Systemic therapy for Merkel cell carcinoma: what's on the horizon? Cancers (Basel) 2014; 6:1180–94.
2. Toberer F, Werchau S, Bischof M et al. Merkel cell carcinoma: a highly aggressive tumor with possible viral etiology. Chirurg 2011; 82:653–60 (in German).
3. Iyer JG, Blom A, Doumani R et al. Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. J Clin Oncol 2014; 32(Suppl. 5):9091.
4. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096–100.
5. Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst 2015;107:pii:dju422.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–64.
7. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 2013; 13:847–61.
8. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521–32.
9. Lipson EJ, Vincent JG, Loyo M et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54–63.
10. Afanasiev OK, Yelistratova L, Miller N et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013; 19:5351–60.
11. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122–33.
12. Nghiem P, Bhatia S, Daud A et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Presented at the 2015 European Cancer Congress. Vienna, Austria, 27 September 2015; abstr. 22LBA.
13. Patnaik A, Kang SP, Rasco D et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21:4286–93.
14. EMD Serono. Avelumab in subjects with Merkel cell carcinoma (JAVELIN Merkel 200). Available at: https://clinicaltrials.gov/ct2/show/NCT02155647 (last accessed 27 June 2016).
15. Lipson EJ, Sharfman WH, Drake CG et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462–8.
16. Triozzi PL, Fernandez AP. The role of the immune response in Merkel cell carcinoma. Cancers (Basel) 2013; 5:234–54.
17. Dowlatshahi M, Huang V, Gehad AE et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 2013; 133:1879–89.
18. + lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29:1539–46.